Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second-line agents for rheumatoid arthritis

S L Scharf1, N Christophidis

  • 1Department of Geriatric Medicine, Alfred Group of Hospitals, Melbourne, VIC.

The Medical Journal of Australia
|August 21, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spontaneous bruising as a possible adverse reaction to memantine.

Internal medicine journal·2005
Same author

Hepatotoxicity possibly due to paracetamol with carbamazepine.

Internal medicine journal·2004
Same author

Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis.

Clinical and experimental rheumatology·1999
Same author

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

Neurology·1999
Same author

Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on human polymorphonuclear leucocyte function in buffer and plasma.

Clinical and experimental rheumatology·1998
Same author

NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant?

Australian and New Zealand journal of medicine·1998

Second-line agents effectively treat persistent synovitis in elderly patients. However, due to increased adverse reaction risks, cautious use with lower doses and frequent monitoring is advised, with corticosteroids offering an alternative.

Area of Science:

  • Rheumatology
  • Geriatric Medicine

Background:

  • Second-line agents (disease-modifying antirheumatic drugs) are standard for persistent synovitis unresponsive to NSAIDs.
  • Elderly patients share similar indications for these agents but face heightened risks of adverse reactions.

Purpose of the Study:

  • To outline the use of second-line agents in elderly patients with persistent synovitis.
  • To highlight the increased risks and necessary precautions for this demographic.

Main Methods:

  • Review of established treatment guidelines for persistent synovitis.
  • Consideration of age-specific risks and management strategies in the elderly population.

Main Results:

  • Indications for second-line agents in the elderly are comparable to younger individuals.

Related Experiment Videos

  • Elderly patients require lower doses, careful selection, and intensified monitoring for adverse events.
  • Low-dose corticosteroids can be effective, potentially avoiding the need for second-line therapies.

    • Conclusions:

    • Treatment of persistent synovitis in the elderly necessitates a modified approach to second-line agent therapy.
    • Emphasis on risk mitigation through dose adjustment, patient selection, and vigilant monitoring is crucial.
    • Corticosteroids present a viable, often safer, alternative for managing synovitis in older adults.